Pooling results from 18 cohorts demonstrated a statistically significant mortality disadvantage of carrying MGMT promoter unmethylation versus MGMT promoter methylation (HR = 2.30, 95% CI: 1.90–2.78, p < 0.0001) among GBM patients receiving immunotherapy (Figure 2A). The gene discussed is MGMT; the disease is glioblastoma.